China Finance Inc
Change company Symbol lookup
Select an option...
CHFI China Finance Inc
SU Suncor Energy Inc
CUBI Customers Bancorp Inc
SMIT Schmitt Industries Inc
BA Boeing Co
AMSWA American Software Inc
V Visa Inc
SVFB SVF Investment Corp 2
DMO Western Asset Mortgage Opportunity Fund Inc
SHAK Shake Shack Inc

Financials : Capital Markets |
Company profile

China Finance, Inc., through its wholly owned subsidiary, Shenzhen Hua Yin Guaranty and Investment Limited Liability Corporation (SHY), is engaged in providing surety guarantees for privately owned small and medium enterprises (SMEs) (or operating companies) in the People’s Republic of China entering into transactions, whereby the SME will be acquired by a publicly traded United States reporting company in a reverse merger or other merger and acquisition transaction; providing loan guarantees to assist SMEs and individuals in China in obtaining loans from Chinese banks for business operations and/or personal use, and making direct loans to SMEs for business operations. In addition, the Company is seeking direct investments (including, without limitation, controlling investments) in SMEs that would be made through the Company’s wholly owned subsidiary, Value Global International Limited.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

China's Lunar New Year celebrations raise concerns about COVID spread, while officials say peak is past

2:40 pm ET January 25, 2023 (MarketWatch)

By Ciara Linnane

U.S. COVID cases are down 30% from two weeks ago, solidifying recent downtrend

A few days into the first Lunar New Year holiday since the lifting of pandemic restrictions in China, Chinese consumers are eager to travel but are also wary as a major COVID wave sweeps the nation, MarketWatch's Tanner Brown reported

The 15-day festival is considered the world's largest annual migration, during which students and workers return to their hometowns in droves -- that is, until COVID shut down travel in 2020.

On Saturday, officials said that as much as 80% of the population has been infected since the lifting of restrictions in December, amounting to 1.2 billion people.

On Wednesday, the Chinese Center for Disease Control and Prevention said critically ill COVID cases are down 72% from their peak earlier this month and that daily deaths are down 79% from their peak, as Reuters reported

China has been criticized for underreporting its COVID numbers since the start of the pandemic. And its latest fatality numbers only include people who died in hospitals, excluding those who died at home.

In the U.S., the seven-day average of new cases stood at 45,656 on Tuesday, according to a New York Times tracker. That's down 30% from two weeks ago, confirming the recent downtrend.

The daily average for hospitalizations was down 24% to 36,227. The average for deaths was 542, down 7% from two weeks ago.

Cases are currently rising in just five states: Illinois, Tennessee, Kentucky, Alaska and Kansas, along with Washington, D.C., and the U.S. Virgin Islands.

On a per capita basis, they are highest in Tennessee, at 41 new cases per 100,000 residents.

Coronavirus Update: MarketWatch's daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

Other COVID-19 news you should know about:

-- Abbott Laboratories' (ABT) quarterly earnings released Wednesday showed that the headwinds from its baby-formula business and declining sales of COVID-19 tests are still weighing on the company's performance. The company's diagnostics division reported $3.3 billion in revenue, including about $1.1 billion in sales of COVID-19 tests, in the final three months of the year. The FactSet consensus was $2.6 billion. But overall, the company beat profit and revenue expectations.

-- Intuitive Surgical Inc.'s stock (ISRG) was down 7% Wednesday, after the maker of surgical robotic systems missed earnings estimates amid COVID-related disruption. The company said it was able to place 369 of its flagship Da Vinci Surgical Systems, a 4% drop from 385 in the fourth quarter of 2021. Procedures using the system rose about 18%, but the COVID-19 resurgence in China "negatively impacted" procedure volumes in the region. COVID-19 disruptions later in the quarter also affected the U.S. and Europe, the company said.

-- As cases of COVID, flu and respiratory syncytial virus, or RSV, surged in the fall as part of a "tripledemic" in the U.S., demand for cold medications translated to a good quarter for Johnson & Johnson's (JNJ) consumer health business, the company said on Tuesday J & J's over-the-counter division, which includes the pain reliever Motrin and the allergy medicine Zyrtec, had sales of $1.57 billion in the final three months of 2022, up from $1.37 billion in the same quarter of the previous year. It also beat the FactSet consensus of $1.4 billion. (The company does not break out sales for specific products.) The company cited Motrin and Tylenol as "major contributors to growth" for the OTC business in the fourth quarter.

Here's what the numbers say:

The global tally of confirmed cases of COVID-19 topped 669.3 million on Wednesday, while the death toll rose above 6.74 million, according to data aggregated by Johns Hopkins University.

The U.S. leads the world with 102 million cases and 1,105,204 fatalities.

The Centers for Disease Control and Prevention's tracker shows that 229.5 million people living in the U.S., equal to 69.1% of the total population, are fully vaccinated, meaning they have had their primary shots.

So far, just 50.7 million Americans, equal to 15.3% of the overall population, have had the updated COVID booster that targets both the original virus and the omicron variants.

-Ciara Linnane


(END) Dow Jones Newswires

January 25, 2023 14:40 ET (19:40 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.